Zengjun T. Li

National Key Laboratory Of Advanced Drug Delivery System
Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

NMN/NAD+ enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells.

NMN/NAD+ enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells.

Journal: Autophagy

Published: May 25, 2026

Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma.

Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma.

Journal: Haematologica

Published: April 05, 2026

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

Journal: American journal of hematology

Published: February 04, 2026

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.

Journal: Journal of hematology & oncology

Published: December 26, 2025

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies.

Journal: Journal of hematology & oncology

Published: December 26, 2025

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: December 23, 2025

Starvation-induced LHFPL3-AS2 promotes MAPKAP K2-dependent phosphorylation of hnRNPA0 and progression of esophageal squamous cell carcinoma.

Starvation-induced LHFPL3-AS2 promotes MAPKAP K2-dependent phosphorylation of hnRNPA0 and progression of esophageal squamous cell carcinoma.

Journal: Cancer letters

Published: November 01, 2025

Radiofrequency Ablation in the Treatment of Chronic Radiation Enteritis.

Radiofrequency Ablation in the Treatment of Chronic Radiation Enteritis.

Journal: Journal of gastrointestinal cancer

Published: October 21, 2025

Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma.

Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma.

Journal: Frontiers in immunology

Published: September 02, 2025

Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma.

Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma.

Journal: Frontiers in oncology

Published: August 31, 2025

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).

Journal: Blood cancer journal

Published: August 21, 2025

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Journal: EClinicalMedicine

Published: August 15, 2025

Showing 1-12 of 98

Last Updated: 09/26/2026